Media stories about Vanda Pharmaceuticals (NASDAQ:VNDA) have been trending somewhat positive on Saturday, according to Accern Sentiment. The research group ranks the sentiment of press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Vanda Pharmaceuticals earned a coverage optimism score of 0.19 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 46.8801389712071 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

Here are some of the media headlines that may have effected Accern Sentiment’s rankings:

A number of equities research analysts have issued reports on VNDA shares. Zacks Investment Research cut shares of Vanda Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, October 26th. ValuEngine cut shares of Vanda Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, October 26th. Jefferies Group LLC restated a “buy” rating and set a $21.00 price target on shares of Vanda Pharmaceuticals in a report on Tuesday, August 29th. Oppenheimer Holdings, Inc. restated a “buy” rating and set a $21.00 price target on shares of Vanda Pharmaceuticals in a report on Thursday, September 14th. Finally, Piper Jaffray Companies set a $26.00 price target on shares of Vanda Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, October 19th. One research analyst has rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the company’s stock. Vanda Pharmaceuticals presently has an average rating of “Buy” and an average price target of $21.50.

Vanda Pharmaceuticals (NASDAQ VNDA) traded down $0.30 during trading hours on Friday, reaching $12.95. 650,555 shares of the company traded hands, compared to its average volume of 557,575. Vanda Pharmaceuticals has a 52-week low of $11.90 and a 52-week high of $18.99.

Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.10). Vanda Pharmaceuticals had a negative net margin of 9.01% and a negative return on equity of 10.99%. The firm had revenue of $41.30 million during the quarter, compared to analyst estimates of $43.90 million. During the same quarter in the prior year, the business posted ($0.01) earnings per share. The company’s quarterly revenue was up 7.3% compared to the same quarter last year. analysts expect that Vanda Pharmaceuticals will post -0.42 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This report was first reported by Daily Political and is the property of of Daily Political. If you are accessing this report on another publication, it was illegally stolen and republished in violation of US & international copyright and trademark legislation. The original version of this report can be accessed at https://www.dailypolitical.com/2017/11/18/vanda-pharmaceuticals-vnda-earns-daily-news-impact-rating-of-0-19.html.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).

Insider Buying and Selling by Quarter for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.